Anti-C3a / C3a des Arg antibody [K13/16] (ab36385)
Key features and details
- Mouse monoclonal [K13/16] to C3a / C3a des Arg
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-C3a / C3a des Arg antibody [K13/16]
See all C3a / C3a des Arg primary antibodies -
Description
Mouse monoclonal [K13/16] to C3a / C3a des Arg -
Host species
Mouse -
Specificity
Does not cross react with C4a or C5a. -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Full length native protein (purified). This information is proprietary to Abcam and/or its suppliers.
-
Epitope
Recognizes an epitope present on human C3, C3a and C3a(desArg). -
General notes
Effectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40 -
Concentration information loading...
-
Purity
Protein A purified -
Primary antibody notes
Effectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay. -
Clonality
Monoclonal -
Clone number
K13/16 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
sELISA pair antibody
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab36385 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/150.
|
Notes |
---|
IHC-P
1/150. |
Target
-
Function
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. -
Tissue specificity
Plasma. -
Involvement in disease
Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. -
Sequence similarities
Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain. -
Post-translational
modificationsC3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 718 Human
- Omim: 120700 Human
- SwissProt: P01024 Human
- Unigene: 529053 Human
-
Alternative names
- Acylation stimulating protein antibody
- Acylation stimulating protein cleavage product antibody
- ASP antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the of veins of nephritis.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the veins.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the lumen of veins.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/75. Strong staining is visible in the of veins of nephritis.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (5)
ab36385 has been referenced in 5 publications.
- Kemper C & Kolev M Enzymatic Reactions and Detection of C3 Cleavage Fragments. Bio Protoc 4:N/A (2014). PubMed: 29094056
- Elsner J et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24:518-22 (1994). PubMed: 8125125
- Elsner J et al. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83:3324-31 (1994). PubMed: 8193368
- Nezlin R et al. Proteins separated from human IgG molecules. Mol Immunol 30:935-40 (1993). PubMed: 8341284
- Püschel GP et al. Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver. FEBS Lett 243:83-7 (1989). PubMed: 2784112